Deep Track Capital, LP
Deep Track Capital, LP is an investment firm headquartered in Greenwich, Connecticut, specializing in the life sciences industry. Founded in 2020, the firm partners with public and pre-IPO biotechnology companies, providing capital, strategic guidance, and access to networks. The team is led by experienced professionals with backgrounds in healthcare finance and investment. Deep Track Capital employs 19 people and operates with a strong focus on innovation in biotechnology and life sciences, serving institutional investors and company management teams.
Investment Strategy
Deep Track Capital focuses exclusively on the life sciences industry, developing long-term partnerships with management teams of leading public and pre-IPO biotechnology companies. The firm utilizes a fundamentally driven, research-intensive strategy to identify high-potential investments primarily in biotechnology and healthcare sectors. Deep Track Capital invests its time and expertise, often leading transactions and building syndicates, and participates in rounds led by other qualified investors. Its approach centers on generating superior risk-adjusted returns by leveraging industry expertise and expansive networks, targeting companies with strong growth potential and innovative solutions for unmet medical needs.
Latest 13F Filing Activity
Deep Track Capital, LP filed their most recent 13F report on Jun 30, 2025 disclosing 64 equity positions and 1 options positions with a total 13F market value of $3B. The fund increased holdings in Insmed Inc., Axsome Therapeutics Inc., Ionis Pharmaceuticals Inc. among other positions. Deep Track Capital, LP reduced exposure to Intra-cellular Therapies Inc., Bridgebio Pharma Inc., Dynavax Technologies Corp. among others.
Top Holdings
Equity Positions (64)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
G GH | GUARDANT HEALTH INC | 7.09% | $221.2M | 4,250,000 | $27.83 | $52.04 | -$10.7M |
I IONS | IONIS PHARMACEUTICALS INC | 6.20% | $193.3M | 4,891,544 | $34.81 | $39.51 | +$55.6M |
P PTGX | PROTAGONIST THERAPEUTICS INC | 5.75% | $179.4M | 3,245,899 | $45.88 | $55.27 | +$34.3M |
D DVAX | DYNAVAX TECHNOLOGIES CORP | 5.66% | $176.5M | 17,791,486 | $11.54 | $9.92 | -$54.3M |
I INSM | INSMED INC | 5.65% | $176.1M | 1,750,000 | $97.10 | $100.64 | +$156.7M |
Options Positions (1)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
S SRPT | SAREPTA THERAPEUTICS INC | New | Put | $7.7M | 4,500 | $17.10 | $17.10 | +4,500 | +$7.7M |
Industry Allocation
Investment Team (5)
| Name | Role | Location | |
|---|---|---|---|
B Brett Erkman | Managing Director | New York, NY , United States | |
 | Biotech analyst | New York, NY , United States | |
 | Principal | Greenwich, CT , United States | |
R Rael Mazansky | Managing Director | Greenwich, CT , United States | |
 | Principal | Greenwich, CT , United States |